On Wednesday, Shares of Cheetah Mobile Inc (ADR) (NYSE:CMCM), lost -4.48% to $16.41.
Cheetah Mobile, declared a partnership with Carnegie Mellon University that will research innovative mobile advertising techniques precedingitizing the user experience while still seeing raised results. To kick off the partnership, Cheetah Mobile is sponsoring the flagship practicum course for the Information Networking Institute (INI) Master’s program at Carnegie Mellon’s Silicon Valley campus this semester.
This collaborative working relationship with a top university in the U.S. has been a aim of Cheetah Mobile’s CEO, Sheng Fu.
Cheetah Mobile Inc. operates a platform that offer mobile and PC applications for users and global content distribution channels for business partners in China. The company’s suite of applications optimizes mobile and PC Internet system performance and provides real time protection against known and unknown security threats.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), declined -0.13% to $117.82, during its last trading session.
BioMarin Pharmaceutical, declared that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Inc. (Dr. Reddy’s) that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan(R) (sapropterin dihydrochloride) 100mg oral tablets.
Under the terms of the settlement, BioMarin will grant Dr. Reddy’s a non-exclusive license to its patents related to Kuvan to allow Dr. Reddy to market a generic version of sapropterin dihydrochloride 100mg tablets in the U.S. for the indications approved for Kuvan startning at a confidential date in the future, but which is more than five years from recently, or earlier under certain circumstances. Additional details of the agreement remain confidential.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
Finally, Fiserv Inc (NASDAQ:FISV), ended its last trade with 1.27% gain, and closed at $87.38.
Fiserv, declared that it has renewed its partnership with Calgary-based Celero, a leading provider of IT solutions to financial institutions across Canada. The DNATM account processing platform from Fiserv will continue to be the exclusive core account processing foundation for Celero’s 84 credit union and other financial institution clients in Alberta, Saskatchewan and Manitoba.
The seven-year agreement follows a 10-year agreement signed in 2005 and builds upon an already strong and successful track record of Celero providing DNA and a wide range of integrated banking solutions from Fiserv to Canadian financial institutions. The agreement broadens the scope of cooperation between Fiserv and Celero to encompass joint software development projects in addition to the IT outsourcing and business services that Celero provides.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The company’s Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
